Augusto Villanueva
Augusto Villanueva
Verified email at
Cited by
Cited by
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk
J Dupuis, C Langenberg, I Prokopenko, R Saxena, N Soranzo, ...
Nature genetics 42 (2), 105-116, 2010
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ...
The Lancet 394 (10193), 121-130, 2019
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
SM Wilhelm, L Adnane, P Newell, A Villanueva, JM Llovet, M Lynch
Molecular cancer therapeutics 7 (10), 3129-3140, 2008
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
K Schulze, S Imbeaud, E Letouzé, LB Alexandrov, J Calderaro, ...
Nature genetics 47 (5), 505-511, 2015
Patient-derived xenograft models: an emerging platform for translational cancer research
M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ...
Cancer discovery 4 (9), 998-1013, 2014
Gene expression in fixed tissues and outcome in hepatocellular carcinoma
Y Hoshida, A Villanueva, M Kobayashi, J Peix, DY Chiang, A Camargo, ...
New England Journal of Medicine 359 (19), 1995-2004, 2008
Genetic landscape and biomarkers of hepatocellular carcinoma
J Zucman-Rossi, A Villanueva, JC Nault, JM Llovet
Gastroenterology 149 (5), 1226-1239. e4, 2015
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma
Y Hoshida, SMB Nijman, M Kobayashi, JA Chan, JP Brunet, DY Chiang, ...
Cancer research 69 (18), 7385-7392, 2009
Liver cancer cell of origin, molecular class, and effects on patient prognosis
D Sia, A Villanueva, SL Friedman, JM Llovet
Gastroenterology 152 (4), 745-761, 2017
Pivotal role of mTOR signaling in hepatocellular carcinoma
A Villanueva, DY Chiang, P Newell, J Peix, S Thung, C Alsinet, V Tovar, ...
Gastroenterology 135 (6), 1972-1983. e11, 2008
Human polymorphism at microRNAs and microRNA target sites
MA Saunders, H Liang, WH Li
Proceedings of the National Academy of Sciences 104 (9), 3300-3305, 2007
Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features
D Sia, Y Jiao, I Martinez-Quetglas, O Kuchuk, C Villacorta-Martin, ...
Gastroenterology 153 (3), 812-826, 2017
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma
DY Chiang, A Villanueva, Y Hoshida, J Peix, P Newell, B Minguez, ...
Cancer research 68 (16), 6779-6788, 2008
Genomics and signaling pathways in hepatocellular carcinoma
A Villanueva, P Newell, DY Chiang, SL Friedman, JM Llovet
Seminars in liver disease 27 (01), 055-076, 2007
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
JM Llovet, A Villanueva, A Lachenmayer, RS Finn
Nature reviews Clinical oncology 12 (7), 408-424, 2015
Pikarsky Eet al. et al
JM Llovet, J Zucman-Rossi
Hepatocellular carcinoma. Nature Reviews Disease Primers 2, 16018, 2016
Tumour evolution in hepatocellular carcinoma
AJ Craig, J Von Felden, T Garcia-Lezana, S Sarcognato, A Villanueva
Nature reviews Gastroenterology & hepatology 17 (3), 139-152, 2020
β-catenin activation promotes immune escape and resistance to anti–PD-1 therapy in hepatocellular carcinoma
M Ruiz de Galarreta, E Bresnahan, P Molina-Sánchez, KE Lindblad, ...
Cancer discovery 9 (8), 1124-1141, 2019
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes
D Sia, Y Hoshida, A Villanueva, S Roayaie, J Ferrer, B Tabak, J Peix, ...
Gastroenterology 144 (4), 829-840, 2013
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ...
The Lancet 394 (10193), 131-138, 2019
The system can't perform the operation now. Try again later.
Articles 1–20